Updated results from the EMILIA and TH3RESA trials in patients with advanced-stage HER2-positive breast cancer confirm the overall survival benefit and favourable safety profile of T-DM1 after prolonged follow-up durations. The efficacy of T-DM1 as a second or later line of treatment indicates that HER2 is a relevant therapeutic target throughout the course of the disease.

中文翻译：

---

乳腺癌：T-DM1-乳腺癌治疗史上的重要药物

晚期HER2阳性乳腺癌患者的EMILIA和TH3RESA试验的最新结果证实了长期随访后T-DM1的总体生存获益和良好的安全性。T-DM1作为第二或以后的治疗方法的功效表明，HER2是整个疾病过程中的相关治疗靶标。